CM-4307
- Generic Name
- CM-4307
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 1130115-44-4
- Unique Ingredient Identifier
- 41XGO0VS1U
- Background
CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).
- Indication
用于治疗既往未接受过全身系统性治疗的不可手术切除或转移性肝细胞癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 204
- Registration Number
- NCT03602495
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Donafenib for Previously Treated Metastatic Colorectal Cancer
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 536
- Registration Number
- NCT02870582
- Locations
- 🇨🇳
West China Hospital Sichuan, Chengdu, Sichuan, China
🇨🇳the 307th Hospital of Chinese People's Liberation Army, Beijing, Beijing, China
Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT02698111
- Locations
- 🇨🇳
Cancer Hospital of Medical College, Beijing, Beijing, China
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 668
- Registration Number
- NCT02645981
- Locations
- 🇨🇳
West China Hospital Sichuan University, Chengdu, Sichuan, China
🇨🇳The PLA 81 Hospital, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath